Achieving systemic delivery of oncolytic viruses
<p><strong>Introduction:</strong> Oncolytic virotherapy is a selective and powerful tool for cancer treatment. Studies proving the ability of oncolytic viruses (OVs) to target and rapidly kill cancer cells have led to approval of H101 and Imlygic®. Both these OVs are restricted to...
Auteurs principaux: | Hill, C, Carlisle, R |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
Taylor and Francis
2019
|
Documents similaires
-
Investigation of strategies to enhance the delivery of oncolytic vaccinia virus
par: Hill, C
Publié: (2020) -
Polymeric cups for cavitation mediated delivery of oncolytic vaccinia virus
par: Myers, R, et autres
Publié: (2016) -
Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles
par: Mark S. Ferguson, et autres
Publié: (2012-01-01) -
Improving systemic delivery of oncolytic virus by cellular carriers
par: Ziyi Peng, et autres
Publié: (2024-12-01) -
Cavitation-enhanced delivery of a self-amplifying oncolytic adenovirus for tumour-selective cancer therapy.
par: Carlisle, R, et autres
Publié: (2012)